Other Clinical Trial - IMPACT-AML: Randomized Pragmatic Clinical Trial for

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT02890329` - Ipilimumab and Decitabine in Treating Patients With Relapsed or Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia	Phase 1
Active, not recruiting	`NCT04975919` - Venetoclax in Combination With Decitabine and Cedazuridine for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia	Phase 2
Terminated	`NCT02882321` - Oxidative Phosphorylation Inhibitor IACS-010759 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia	Phase 1
Recruiting	`NCT03214562` - Venetoclax With Combination Chemotherapy in Treating Patients With Newly Diagnosed or Relapsed or Refractory Acute Myeloid Leukemia	Phase 1/Phase 2
Active, not recruiting	`NCT03289910` - Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Disorders and Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia	Phase 2
Completed	`NCT02756572` - Early Allogeneic Hematopoietic Cell Transplantation in Treating Patients With Relapsed or Refractory High-Grade Myeloid Neoplasms	Phase 2
Completed	`NCT02509546` - 8-Chloroadenosine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia	Phase 1/Phase 2
Recruiting	`NCT03683433` - Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation	Phase 2
Completed	`NCT02551718` - High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia	N/A
Completed	`NCT02070458` - Ixazomib, Mitoxantrone Hydrochloride, Etoposide, and Intermediate-Dose Cytarabine in Relapsed or Refractory Acute Myeloid Leukemia	Phase 1
Terminated	`NCT03557970` - JNJ-40346527 in Treating Participants With Relapsed or Refractory Acute Myeloid Leukemia	Phase 2
Recruiting	`NCT03661307` - Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome	Phase 1/Phase 2
Recruiting	`NCT03629171` - Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid Leukemia	Phase 2
Recruiting	`NCT05396859` - Entrectinib in Combination With ASTX727 for the Treatment of Relapsed/Refractory TP53 Mutated Acute Myeloid Leukemia	Phase 1
Terminated	`NCT03067571` - Daratumumab in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome	Phase 2
Completed	`NCT04146038` - Salsalate, Venetoclax, and Decitabine or Azacitidine for the Treatment of Acute Myeloid Leukemia or Advanced Myelodysplasia/Myeloproliferative Disease	Phase 2
Suspended	`NCT03128034` - 211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia	Phase 1/Phase 2
Active, not recruiting	`NCT04207190` - Talazoparib and Gemtuzumab Ozogamicin for the Treatment of CD33 Positive Relapsed or Refractory Acute Myeloid Leukemia	Phase 1
Recruiting	`NCT04047641` - Cladribine, Idarubicin, Cytarabine, and Quizartinib in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome	Phase 1/Phase 2
Withdrawn	`NCT04493099` - Alvocidib in Combination With Decitabine and Venetoclax in Patients With Relapsed or Refractory AML or as Frontline Therapy in Unfit Patients With AML	Phase 1/Phase 2

NCT number	NCT06418776
Study type	Interventional
Source	National Research Center for Hematology, Russia
Contact	Anastasia Kashlakova, MD
Phone	+79629087553
Email	kashlakova.a.i@gmail.com
Status	Recruiting
Phase	Phase 3
Start date	April 1, 2024
Completion date	May 2029

IMPACT-AML: Randomized Pragmatic Clinical Trial for Relapsed or Refractory AML

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms